Combining structure and function to evaluate glaucomatous progression: implications for the design of clinical trials

Página do item simplificado
dc.contributor.authorLisboa, Renato [UNIFESP]
dc.contributor.authorWeinreb, Robert N.
dc.contributor.authorMedeiros, Felipe A.
dc.contributor.institutionUniv Calif San Diego
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:31:13Z
dc.date.available2016-01-24T14:31:13Z
dc.date.issued2013-02-01
dc.description.abstractThe selection of a suitable method for assessment of glaucomatous progression and estimation of rates of change is an essential component of the design of clinical trials investigating neuroprotective therapies for the disease. Due to the limitations of currently available tests, approaches combining structural and functional tests are essential in order to provide reliable detection of endpoints. This could also potentially enable shorter clinical trials with relatively smaller sample size requirements. A recent approach for estimating rates of retinal ganglion cell loss using a combination of structural and functional tests has been shown to perform better than isolated parameters from conventional tests for diagnosing, staging and detecting glaucoma progression and may prove useful as an outcome measure in clinical trials of the disease.en
dc.description.affiliationUniv Calif San Diego, Hamilton Glaucoma Ctr, San Diego, CA 92103 USA
dc.description.affiliationUniv Calif San Diego, Dept Ophthalmol, San Diego, CA 92103 USA
dc.description.affiliationUniversidade Federal de São Paulo, Dept Ophthalmol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Ophthalmol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipNIH/NEI
dc.description.sponsorshipResearch to Prevent Blindness (New York, NY)
dc.description.sponsorshipCarl-Zeiss Meditec, Inc
dc.description.sponsorshipIDNIH/NEI: EY021818 (FAM)
dc.format.extent115-122
dc.identifierhttp://dx.doi.org/10.1016/j.coph.2012.10.010
dc.identifier.citationCurrent Opinion in Pharmacology. Oxford: Elsevier B.V., v. 13, n. 1, p. 115-122, 2013.
dc.identifier.doi10.1016/j.coph.2012.10.010
dc.identifier.issn1471-4892
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/35930
dc.identifier.wosWOS:000314329300018
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofCurrent Opinion in Pharmacology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.titleCombining structure and function to evaluate glaucomatous progression: implications for the design of clinical trialsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos